Last updated: 2026-10-09 04:50:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Contineum Therapeutics, Inc. (CTNM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13,20, with a market capitalization of $475,91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8,60 to $17,79. This page covers its latest market performance, valuation, price trends and company information.
$475,91M | |
$12,55 | |
$22,00 | |
$3,35 | |
$12,73 | |
845,26K | |
506,44K | |
-- | |
$17,79 | |
$8,60 | |
-- | |
-- |
Contineum Therapeutics, Inc. (CTNM) last closed at $12,73 as of 2026-10-08 23:31:00, unchanged from the previous close of $12,73.
During the latest regular trading session, CTNM traded between $3,35 and $22,00, with a volume of 845,26K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Contineum Therapeutics, Inc. (CTNM) moved from $11,50 to $13,20, representing a gain of 14,81% ($1,70).
The stock traded between $10,84 and $14,21 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 857,20 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 50,1%
CTNM is currently trading at $13,20, placing it 50,1% of the way from its 52-week low of $8,60 to its 52-week high of $17,79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 51 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Contineum Therapeutics, Inc. (CTNM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.